Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3278581
Max Phase: Preclinical
Molecular Formula: C48H76N14O13
Molecular Weight: 1057.22
Molecule Type: Protein
Associated Items:
ID: ALA3278581
Max Phase: Preclinical
Molecular Formula: C48H76N14O13
Molecular Weight: 1057.22
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Standard InChI: InChI=1S/C48H76N14O13/c1-24(2)19-32(59-41(69)30-15-16-38(66)56-30)42(70)54-27(6)40(68)61-35(23-63)45(73)60-34(21-28-11-13-29(64)14-12-28)43(71)55-26(5)39(67)58-33(20-25(3)4)44(72)57-31(9-7-17-52-48(50)51)47(75)62-18-8-10-36(62)46(74)53-22-37(49)65/h11-14,24-27,30-36,63-64H,7-10,15-23H2,1-6H3,(H2,49,65)(H,53,74)(H,54,70)(H,55,71)(H,56,66)(H,57,72)(H,58,67)(H,59,69)(H,60,73)(H,61,68)(H4,50,51,52)/t26-,27+,30+,31+,32+,33+,34+,35+,36+/m1/s1
Standard InChI Key: YSNPPUBHYQXRPY-LBHRLENNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1057.22 | Molecular Weight (Monoisotopic): 1056.5716 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Humphries J, Wan YP, Folkers K.. (1977) Inhibition of the activity of the luteinizing hormone-releasing hormone (LH-RH) by analogues with variations at positions 2, 3, and 6 and the carboxyl terminus., 20 (7): [PMID:327068] [10.1021/jm00217a024] |
Source(1):